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1 Research fellow of the Japan Society for the PromoHuman islet amyloid polypeptide (hIAPP) is the primary component of the amyloid deposits found
in the pancreatic islets of patients with type 2 diabetes mellitus. However, it is unknown how amy-
loid ﬁbrils are formed in vivo. In this study, we demonstrate that gangliosides play an essential role
in the formation of amyloid deposits by hIAPP on plasma membranes. Amyloid ﬁbrils accumulated
in ganglioside- and cholesterol-rich microscopic domains (‘lipid rafts’). The depletion of ganglio-
sides or cholesterol signiﬁcantly reduced the amount of amyloid deposited. These results clearly
showed that the formation of amyloid ﬁbrils was mediated by gangliosides in lipid rafts.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The deposition of insoluble amyloid ﬁbrils in tissues is a hall-
mark of a range of diseases referred to as amyloidoses, that include
type II diabetes mellitus (DM), Alzheimer’s disease, and transmis-
sible spongiform encephalopathy [1–4]. The misfolding of a unique
peptide or protein into b-sheet-rich ﬁbrous structures is proposed
to be a key step in the onset and development of these diseases
[3,5]. The amyloid deposits cause cell dysfunction, death, and sub-
sequently severe impairment in tissues of patients. Elucidation of
amyloid formation mechanisms, which are still poorly understood,
is essential for prevention of the onset and development of
amyloidoses.
Native human islet amyloid polypeptide (hIAPP) is the primary
component of the amyloid deposits [6,7] found in the pancreatic is-
let of patients with type 2 DM [8,9]. The causal relationship be-
tween the formation of amyloid ﬁbrils containing hIAPP and thechemical Societies. Published by E
le’s medium; CHO, Chinese
holera toxin subunit B; DIC,
tus; DMEM, Dulbecco’s Mod-
hIAPP, human islet amyloid
linylmethyl)-2-phenylethyl]-
. Matsuzaki).
tion of Science.onset of type 2 DM has not been resolved. However, the amyloid
deposits cause cellular dysfunction, suggesting that their forma-
tion is involved in the pathological process. It should be noted that
the physiological concentration of hIAPP might not be high enough
to cause self-aggregation. Accumulating evidence has suggested
that membrane lipids play a crucial role in the formation of amy-
loid ﬁbrils [10]. Experiments in vitro demonstrated that two nega-
tively charged lipid species, phosphatidylglycerol (PG) [11], and
phosphatidylserine (PS) [12], signiﬁcantly facilitate the production
of amyloid by hIAPP. However, neither lipid is expressed in the
outer leaﬂets of plasma membranes of mammalian cells. Therefore,
other lipid species would induce the amyloidogenesis on cell mem-
branes. In the case of Alzheimer’s amyloid b-protein, gangliosides
in lipid microdomains (‘lipid rafts’) mediated the protein’s aggrega-
tion [13]. Lipid rafts are composed of sphingomyelin, gangliosides,
and cholesterol [14] and considered to be a platform of a large
number of events in plasma membranes, including signal trans-
ductions and viral assembly and budding [15–17]. The formation
of amyloid ﬁbrils by hIAPP is also possibly mediated by ganglio-
sides in lipid rafts on live cell membranes.
In this study, we visualized hIAPP amyloid deposits on cell
membranes. Amyloid ﬁbrils accumulated in ganglioside- and cho-
lesterol-rich domains in a concentration-dependent manner, lead-
ing to cell death. The depletion of gangliosides or cholesterol
signiﬁcantly reduced the amount of hIAPP accumulated.lsevier B.V. All rights reserved.
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2.1. Materials
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM), horse serum, bo-
vine serum, penicillin, and streptomycin were purchased from
Invitrogen (Carlsbad, CA). Alpha modiﬁcation of Eagle’s medium
(aMEM) and Congo red were obtained from ICN Biomedicals (Aur-
ora, OH) and Nacalai Tesque (Kyoto, Japan), respectively. HIAPP
(purity > 95%) was purchased from Peptide Institute (Minou, Ja-
pan). Alexa Fluor 647-conjugated cholera toxin subunit B (CTX-B)
and Calcein-AM were obtained from Molecular Probes (Eugene,
OR). Hexaﬂuoroisopropanol (HFIP) was purchased from Sigma
(St. Louis, MO). N-[2-Hydroxy-1-(4-morpholinylmethyl)-2-phenyl-
ethyl]-decanamide hydrochloride (PDMP) and compactin (meva-
statin) were obtained from Wako (Osaka, Japan) and Pierce
(Rockford, IL), respectively.
2.2. Peptide solutions
In order to prepare stock solutions of aggregate-free hIAPP, the
peptide was ﬁrst dissolved in HFIP at 500 lM and aliquots of the
solution were nitrogen-evaporated to completely remove the sol-
vent. Peptide stock solutions were stored at 80 C prior to use.
Just before the experiment, hIAPP was dissolved in 10 mM sodium
phosphate buffer and pH was adjusted to pH 10 with 1 M NaOH
[18].
To conﬁrm the absence of any pre-aggregated peptide, prepared
stock solution of hIAPP was fractionated with a Superdex 75 10/
300 GL column with an exclusion limit of 40 000 Da, which had
been pretreated with an excess of BSA to block non-speciﬁc bind-
ing of peptides. The column was eluted with Tris buffered saline
(TBS) at a ﬂow rate of 0.5 mL/min and the peptide was detected
by measuring UV absorbance at 220 nm. Molecular mass was esti-
mated with FITC-dextrans (M.W. 4400, 21 200, 42 000) as stan-
dards. The blank chromatographs were subtracted. From the
prepared solution, any oligomers and aggregates were not detected
(data not shown).2.3. Cell culture and sample preparation
Rat pheochromocytoma PC12 cells were cultured in DMEM con-
taining 5% horse serum, 10% bovine serum, 100 units/mL penicillin,
and 0.1 mg/mL of streptomycin at 37 C with 5% CO2. Chinese ham-
ster ovary (CHO) cells were cultured in aMEM containing 10% fetal
bovine serum, 100 U/mL penicillin, and 0.1 mg/mL of streptomycin
at 37 C with 5% CO2. After being plated at a density of 100 000
cells onto a poly-D-lysine-coated 35-mm glass-bottomed dish, cells
were incubated for 24 h at 37 C with 5% CO2. Unless otherwise
noted, PC12 and CHO cells were incubated with reagents in the
medium at 37 C with 5% CO2 and washed twice with TBS. The cells
were stained with ﬂuorophores in TBS at room temperature and
washed twice with TBS.2.4. Cell staining
Cells were incubated with freshly prepared hIAPP and subse-
quently stained with 20 lM Congo red (excitation, 543 nm; emis-
sion, band pass ﬁlter (BP) 560–615 nm) for 30 min. Labeling of
cell surface gangliosides was performed by incubating the cells
with 10 lg/mL CTX-B (excitation, 633 nm; emission, LP 650 nm)
for 20 min. Fluorescently labeled cells were visualized using the
63 C-Apochromat objective of a Zeiss LSM 5 PASCAL confocal la-
ser scanning microscope, and in double-labeling experiments, the
multi-tracking mode was selected, unless otherwise noted.2.5. Interaction of preincubated hIAPP with cells
Ten micromolar hIAPP was preincubated in medium for 24 h at
37 C with 5% CO2. The incubated peptides were directly applied to
plated PC12 cells and further incubated for 30 min at 37 C with 5%
CO2. GM1 labeling was performed as described above.
2.6. Inhibition of gangliosides or cholesterol synthesis
PC12 cells were incubated with 20 lM PDMP for 24 h or 1 lM
compactin for 48 h, which inhibited gangliosides or cholesterol
synthesis, respectively. The compactin-treatment was reported to
reduce the cellular cholesterol level to about 40% of the normal le-
vel without affecting the viability [19]. The reagent-containing
medium was replaced with fresh medium containing 20 lM hIAPP
and the cells were incubated for 24 h. Cell staining was performed
as described above.2.7. Estimation of ganglioside content and accumulated amount of
hIAPP amyloids
The amount of cell surface gangliosides and accumulated hIAPP
amyloids were estimated by the ﬂuorescence intensity of bound
CTX-B and Congo red, respectively [20,21]. The background ﬂuo-
rescence was subtracted from the CTX-B or Congo red ﬂuorescence
expressed in 256 tones pixel by pixel. The intensity multiplied by
the pixel number was summed and normalized to the cell number
examined. This value reﬂects the quantity of gangliosides or accu-
mulated hIAPP amyloids per cell.3. Results and discussion
Ganglioside-expressing PC12 cells were incubated with 10 lM
hIAPP for 24 h, and subsequently stained with Congo red and
CTX-B, the former being suitable for staining amyloids in live cells
[13] and the latter being a speciﬁc probe for gangliosides. The dis-
tribution of gangliosides on PC12 cell membranes is heterogenous
(Fig. 2A, PC12 untreated). Ganglioside-rich domains, in which gan-
gliosides are brightly stained with CTX-B, are also cholesterol-rich
and abolished by cholesterol depletion [13,22], suggesting that the
microscopic domains were assemblies of nano-scale membrane
patches, called ‘lipid raft’ [23]. hIAPP speciﬁcally accumulated in
the ganglioside- and cholesterol-rich domains in PC12 cell mem-
branes, forming amyloid ﬁbrils (Fig. 1A). Fig. 1B shows the concen-
tration-dependent accumulation of the amyloid. At a concentration
of 25 lM, hIAPP was clearly cytotoxic, as judged from differential
interference contrast (DIC) images and ﬂuorescence micrographs
of a live cell indicator, calcein-AM (data not shown). The peptide-
induced cytotoxicity was observed after hIAPP amyloid had accu-
mulated on cell membranes to some extent, suggesting that the
native cytotoxic form of hIAPP was produced during the process
of the peptide aggregation into Congo red-positive amyloids. Addi-
tionally, on the pathway of amyloidogenesis, hIAPP does not form
small oligomers [24], indicating that the cytotoxic form was possi-
bly amyloid ﬁbrils.
To examine whether hIAPP initially bound to and then accumu-
lated on cell membranes, or initially aggregated in the medium and
then bound to the membranes, hIAPP was preincubated in medium
for 24 h and then applied to PC12 cells. No accumulation of amy-
loid was observed (Fig. 1C), indicating that hIAPP formed amyloids
on ganglioside- and cholesterol-rich domains and ﬁbrils formed in
solution were not the main toxic components.
To investigate whether gangliosides and cholesterol were
essential for the accumulation of hIAPP amyloid on cell mem-
branes, PC12 cells were treated with PDMP, an inhibitor of gangli-
Fig. 1. Accumulation of hIAPP amyloids on PC12 cell membranes. (A) PC12 cells were incubated with 10 lM hIAPP for 24 h and stained with Congo red and CTX-B. (B) PC12
cells were incubated with hIAPP at the indicated concentrations for 24 h and stained with Congo red. (C) Ten micromolar hIAPP was preincubated in culture medium for 24 h,
and then applied to PC12 cells for 30 min.
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and then incubated with 20 lM hIAPP. PDMP signiﬁcantly reduced
the amount of ganglioside to about 43% of control (Fig. 2A). The
compactin-treatment was reported to reduce the cellular choles-
terol level to about 40% of the normal level without affecting the
viability [19] and we have found that inhibiting the synthesis of
cholesterol reduced ganglioside content [13]. According to the de-
crease in ganglioside and cholesterol contents, the accumulation of
hIAPP amyloids was signiﬁcantly suppressed (Fig. 2B). PDMP- and
compactin-treatment lowered the amount of hIAPP accumulated
to 28% and 36% of the control level, respectively.
CHO cells, which express no ganglioside, were also incubated
with 20 lM hIAPP for 24 h, and subsequently stained with Congo
red and CTX-B. CHO cell membranes were not stained with CTX-
B (Fig. 2A), and hIAPP amyloid did not accumulate on the mem-
branes (Fig. 2B).
These results clearly showed that gangliosides and cholesterol
playedcrucial roles in the formationof amyloidﬁbrils byhIAPP. Both
gangliosides and cholesterol are components of lipid rafts in plasma
membrane and thedepletion of each lipid reduced the accumulation
of amyloid, evidently indicating that gangliosides in lipid rafts were
the cause of the formation of amyloid by hIAPP. The ganglioside-in-
duced production of amyloid ﬁbrils is also supported by the ﬁndings
that amountsof gangliosidesweremarkedlygreater inpancreatic is-
lets than in pancreatic tissues [25] and the deposition of hIAPP amy-
loid was speciﬁc to pancreatic islet b cells [8,9].
Sparr et al. demonstrated using rat insulinoma tumor (RIN) cell
that the presence of cell membranes promoted the formation of
amyloid by hIAPP and the amyloidogenesis was coupled to the
extraction of membrane lipids and the subsequent permeabiliza-
tion of the lipid membranes, leading to cytotoxicity [26]. Recently,
the uptake of membrane lipids of pancreatic b-cell line INS-1E dur-
ing the aggregation of hIAPP was also reported [27]. In the case of
Alzheimer’s amyloid b-protein, ganglioside-bound form promotes
the protein aggregation and cytotoxicity [28]. In this study, PC12cell membranes containing gangliosides induced the amyloid for-
mation by hIAPP.
Moreover, it was reported that the amino acid sequences
responsible for amyloid formation and membrane disruption are
located in different regions of the peptide and amyloid formation
can occur independently from membrane disruption [29,30]. The
C-terminal domain has amyloidogenic property, and the N-termi-
nal fragment of hIAPP was alone sufﬁcient to induce membrane
perturbation and a single mutation abolished the activity [31–
33]. The interaction of the N-terminal part of hIAPP with mem-
branes is driven by electrostatic interactions. However, model lipid
membranes used in these reports include only PG as an anionic li-
pid, which is not expressed in the outer leaﬂets of plasma mem-
branes of mammalian cells. Another anionic lipid, PS, has also
been proposed as an inducer of amyloid formation and subsequent
cell death by hIAPP and amyloid b-protein [12,34,35]. However, PS
constitutively exists in the inner leaﬂets and its exposure to the
outer leaﬂets implies apoptotic cell death, suggesting that the
interaction of the peptides with PS may not be considered as the
primary cause of extracellular amyloid deposits and cell death in
intact islet cells. Therefore, the interaction of N-terminal region
of hIAPP with the membranes would be mediated by gangliosides,
which are major anionic lipids of mammalian cell membranes.
Gangliosides in lipid rafts are clustered [36] and the local electro-
static interaction with hIAPP would be signiﬁcantly enhanced.
These ﬁndings possibly indicate the existence of two independent
processes. hIAPP preferentially binds to gangliosides in lipid rafts
by electrostatic interactions and the ganglioside-bound peptide
facilitates the amyloid formation. During amyloid formation pro-
cess, hIAPP takes up membrane lipids, permeabilizes the mem-
branes, and leads to cell death. Accelerated binding of hIAPP to
cell surface gangliosides ultimately, albeit indirectly, elicits the en-
hanced cytotoxicity. We previously reported that ganglioside-
bound form of amyloid b-protein generates negative curvature
strain on lipid bilayers [37]. hIAPP also provokes negative mem-
Fig. 2. Gangliosides- and cholesterol-dependent accumulation of hIAPP amyloids on plasma membranes. (A) Cell surface gangliosides of PC12 or CHO cells in the indicated
conditions were stained with CTX-B. Ganglioside contents were estimated from CTX-B ﬂuorescence intensity. See Section 2 for details. The data shown are the means ± S.D.
(n = 4). P(untreated versus PDMP-treated) < 0.01. The statistical analysis was performed by the two-sample t-test. (B) PC12 or CHO cells in the indicated conditions were
incubated with 20 lM hIAPP for 24 h and then stained with Congo red. The amount of accumulated hIAPP amyloid was estimated from Congo red ﬂuorescence intensity. See
Section 2 for details. The data shown are the means ± S.D. (n = 3). P(untreated versus PDMP-treated) < 0.02, P(untreated versus compactin-treated) < 0.02. The statistical
analysis was performed by the two-sample t-test.
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might contribute to the hIAPP-induced cytotoxic effect.
In conclusion, we demonstrated that gangliosides in lipid rafts
serve as a platform for the formation of amyloid deposits and the
resultant cytotoxic activity not only with Alzheimer’s amyloid b-
protein [13] but also with hIAPP suggesting this raft-mediated
amyloidogenesis to be a universal mechanism for amyloidogenic
proteins.
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